Imatinib-based chemotherapy regimens for de novo Philadelphia chromosome–positive acute lymphocytic leukemia (Ph+ ALL).
| . | . | Imatinib dosing . | . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|
| Subtype . | Chemo-therapy regimen . | Induction . | Consolidation . | Maintenance . | No. . | CR, % . | Relapse, % . | DFS, % (at y) . | Survival, % (at y) . |
| Abbreviations: C, concurrent; A, alternating; NR, not reported; NA, not applicable; JALSG, Japan Adult Leukemia Study Group; GMALL, German Multi-Centre Acute Lymphoblastic Leukemia; hyper-CVAD, fractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone; GRAAPH, Group for Research on Adult Acute Lymphoblastic Leukemia, GIMEMA, Gruppo Italiano Malattie EMatologiche dell’Adulto; GRAALL, Group for Research in Adult Acute Lymphoblastic Leukemia; Pred, prednisone | |||||||||
| Adults (all) | |||||||||
| Thomas et al28,29 | Hyper-CVAD | C | C | C | 39 | 92 | 14 | 83 (3) | 55 (3) |
| Adults (age < 65 years) | |||||||||
| Yanada et al31,43 | JALSG ALL202 | C | A | C | 80 | 96 | 26 | 60 (1) 51 (2) | 76 (1) 58 (2) |
| Lee et al30 | Modified Linker | C | C | C | 20 | 95 | 32 | 62 (2) | 59 (2) |
| Wassmann et al32 | GMALL | ||||||||
| Alternating | None | A | NR | 47 | NA | NR | 52 (2) | 36 (2) | |
| Concurrent | None | C | NR | 45 | NA | NR | 61 (2) | 43 (2) | |
| de Labarthe et al35 | GRAAPH-2003 | None | C | NR | 45 | 96 | 19 | 51 (1.5) | 65 (1.5) |
| Elderly (> 55 yrs) | |||||||||
| Ottmann et al41 | GMALL | ||||||||
| Chemotherapy | None | C | C | 28 | 96 | 41 | 29 (1.5) | 35 (1.5) | |
| Imatinib | Only | C | C | 27 | 50 | 54 | 57 (1.5) | 41 (1.5) | |
| Vignetti et al40 | GIMEMA | + Pred | Only | Only | 30 | 100 | 48 | 48 (1) | 74 (1) |
| Delannoy et al39 | GRAALL AFR09 | None | C | A | 30 | 72 | 60 | 58 (1) | 66 (1) |
| . | . | Imatinib dosing . | . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|
| Subtype . | Chemo-therapy regimen . | Induction . | Consolidation . | Maintenance . | No. . | CR, % . | Relapse, % . | DFS, % (at y) . | Survival, % (at y) . |
| Abbreviations: C, concurrent; A, alternating; NR, not reported; NA, not applicable; JALSG, Japan Adult Leukemia Study Group; GMALL, German Multi-Centre Acute Lymphoblastic Leukemia; hyper-CVAD, fractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone; GRAAPH, Group for Research on Adult Acute Lymphoblastic Leukemia, GIMEMA, Gruppo Italiano Malattie EMatologiche dell’Adulto; GRAALL, Group for Research in Adult Acute Lymphoblastic Leukemia; Pred, prednisone | |||||||||
| Adults (all) | |||||||||
| Thomas et al28,29 | Hyper-CVAD | C | C | C | 39 | 92 | 14 | 83 (3) | 55 (3) |
| Adults (age < 65 years) | |||||||||
| Yanada et al31,43 | JALSG ALL202 | C | A | C | 80 | 96 | 26 | 60 (1) 51 (2) | 76 (1) 58 (2) |
| Lee et al30 | Modified Linker | C | C | C | 20 | 95 | 32 | 62 (2) | 59 (2) |
| Wassmann et al32 | GMALL | ||||||||
| Alternating | None | A | NR | 47 | NA | NR | 52 (2) | 36 (2) | |
| Concurrent | None | C | NR | 45 | NA | NR | 61 (2) | 43 (2) | |
| de Labarthe et al35 | GRAAPH-2003 | None | C | NR | 45 | 96 | 19 | 51 (1.5) | 65 (1.5) |
| Elderly (> 55 yrs) | |||||||||
| Ottmann et al41 | GMALL | ||||||||
| Chemotherapy | None | C | C | 28 | 96 | 41 | 29 (1.5) | 35 (1.5) | |
| Imatinib | Only | C | C | 27 | 50 | 54 | 57 (1.5) | 41 (1.5) | |
| Vignetti et al40 | GIMEMA | + Pred | Only | Only | 30 | 100 | 48 | 48 (1) | 74 (1) |
| Delannoy et al39 | GRAALL AFR09 | None | C | A | 30 | 72 | 60 | 58 (1) | 66 (1) |